…ve received >2 additional courses. ARR at year 8 was 0.18; 85% were relapse-free and 64% were free from 6-month confirmed disability progression. The mean change in EDSS score from core study baseline to year 8 was 0.17; 70% had stable or improved (47%) EDSS scores. In year 8, 89% had no Gd+ lesions and 70% had no new/enlarging T2 lesions. The median cumulative brain volume loss from baseline was -1.06%; brain volume loss was -0.19%/year or less i…

…Aggressive treatment is more effective, but… Dimethyl fumarate – long-term data Examining autoimmunity with alemtuzumab 2-minute walk more sensitive than T25FW Controversies with revised 2017 McDonald criteria The 2017 revisions to the McDonald criteria introduced three important changes: OCBs could be substituted for dissemination in time (DIT) to arrive at a diagnosis of MS; asymptomatic Gd+ lesions could be used when determining dissemination i…

…P1251); fingolimod (P1228); natalizumab (P1232); teriflunomide (P1233); Peg-IFN-1a (P1236); alemtuzumab (P1240) Switching studies: Natalizumab to alemtuzumab (P1194); in progressive MS (P1212); from a second-line agent to alemtuzumab (P1213) Comparative studies: Orals vs. injectables (P1208); dimethyl fumarate vs. teriflunomide (P1215); oral vs. oral (P1265) Clinical trial analyses: SUNBEAM/RADIANCE (ozanimod) (P1191); CARE-MS (alemtuzumab) (P1235…